No abstract

metastasis, and 22 (17%) locally advanced progression; moreover, 78 (60%) had systemic therapy and 103 (79%) had radiation therapy. After exposure to an antiePD-1 agent, 66 (50%) had partial response, and 13 (10%) had complete response (Table II). Disease progression was reported for 17 patients (13%). There were 23 (18%) deaths, of which 12 (52%) were due to disease progression and 4 (17%) were attributed to serious adverse events. 1 Most common adverse events were fatigue (35 patients [27%]), skin rash (24 [18%]), diarrhea (20 [15%]), and nausea (14 [11%]).Study limitations include risk of bias due to selective outcome reporting inherent to case reports/ series (46 patients [35%]) and few clinical trials. Furthermore, much of the data was limited by sparse reporting (Table I and Table II footnotes).The search also revealed 10 ongoing clinical trials and 1 expanded-access protocol for antiePD-1 agents (alone or in combination) for the treatment of cSCC.In conclusion, findings from the evidence to date warrants continuing investigations of antiePD-1 immunotherapy in the treatment of metastatic, unresectable, or locally advanced cSCC because 60% have had disease response, most commonly with mild adverse events.

No abstract